CA2276467A1 - Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol - Google Patents

Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol Download PDF

Info

Publication number
CA2276467A1
CA2276467A1 CA002276467A CA2276467A CA2276467A1 CA 2276467 A1 CA2276467 A1 CA 2276467A1 CA 002276467 A CA002276467 A CA 002276467A CA 2276467 A CA2276467 A CA 2276467A CA 2276467 A1 CA2276467 A1 CA 2276467A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
heteroaryl
independently
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002276467A
Other languages
English (en)
Inventor
Mark E. Mcgovern
Rene Belder
Bruce D. Behounek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2276467A1 publication Critical patent/CA2276467A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode de prévention ou de réduction du risque d'apparition de maladies cardio-vasculaires par l'administration d'un inhibiteur de protéine de transfert microsomale (MTP) seul ou en combinaison avec un autre médicament réduisant le cholestérol tel qu'un inhibiteur de la HMG CoA-réductase, dont la pravastatine, à un patient qui peut présenter ou non un ou plusieurs facteurs de risque pour un accident coronaire et/ou cérébro-vasculaire tel que l'hypercholestérolémie.
CA002276467A 1997-01-17 1998-01-12 Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol Abandoned CA2276467A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3559297P 1997-01-17 1997-01-17
US60/035,592 1997-01-17
PCT/US1998/000524 WO1998031366A1 (fr) 1997-01-17 1998-01-12 Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol

Publications (1)

Publication Number Publication Date
CA2276467A1 true CA2276467A1 (fr) 1998-07-23

Family

ID=21883624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002276467A Abandoned CA2276467A1 (fr) 1997-01-17 1998-01-12 Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol

Country Status (5)

Country Link
EP (1) EP0989852A4 (fr)
JP (1) JP2001508795A (fr)
AU (1) AU727895B2 (fr)
CA (1) CA2276467A1 (fr)
WO (1) WO1998031366A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304505A1 (fr) * 1997-09-24 1999-04-01 Nova Molecular, Inc. Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives
WO1999063929A2 (fr) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
EP1601668B1 (fr) 2003-03-07 2008-08-27 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517572C (fr) 2003-03-07 2011-12-13 Schering Corporation Composes d'azetidinone substitues, leurs formulations et leur utilisation pour traiter l'hypercholesterolemie
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
EP1951220A2 (fr) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Compositions destinees a l'abbaissement du cholesterol serique et/ou des triglycerides
CN111187200A (zh) * 2020-04-09 2020-05-22 南京昊绿生物科技有限公司 一种洛美他派-d8的合成方法
US20230285376A1 (en) 2020-07-29 2023-09-14 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
CA2091102C (fr) * 1992-03-06 2009-05-26 John R. Ii Wetterau Proteine de transfert de triglycerides microsomaux
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein

Also Published As

Publication number Publication date
AU727895B2 (en) 2001-01-04
WO1998031366A1 (fr) 1998-07-23
JP2001508795A (ja) 2001-07-03
EP0989852A4 (fr) 2002-11-13
EP0989852A1 (fr) 2000-04-05
AU6239798A (en) 1998-08-07

Similar Documents

Publication Publication Date Title
AU727895B2 (en) Method for treating atherosclerosis with an MPT inhibitor and cholesterol lowering drugs
US5883109A (en) Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6057339A (en) Method of inhibiting or treating phytosterolemia with an MTP inhibitor
US5130333A (en) Method for treating type II diabetes employing a cholesterol lowering drug
US5691375A (en) Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5190970A (en) Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5461039A (en) Method for treating hypertension employing a cholesterol lowering drug
US5157025A (en) Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
EP0457514B1 (fr) Procédé pour prévenir, stabiliser ou causer la régression de l'athérosclérose par utilisation d'une association d'un médicament hypocholestérolémique et un inhibiteur ACE
US20030109543A1 (en) Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
EP0482498A2 (fr) Méthode pour prévenir les complications diabétiques, en utilisant un agent réduisant le taux du cholestérol, seul ou en combinaison avec un inhibiteur de l'enzyme de conversion de l'angiotensine
WO1998001119A2 (fr) Compositions pharmaceutiques
AU748608B2 (en) MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels
US5990110A (en) Method for treating tumors having high LDL requirements employing MTP inhibitors
KR20060118557A (ko) 의약 조성물 및 조합물
WO1998031225A1 (fr) Procede pour inhiber ou traiter la phytosterolemie avec un inhibiteur de mtp
CA2291471A1 (fr) Diminution des concentrations de lipoproteine(a) dans le sang
WO1998003174A1 (fr) Procede de traitement de tumeurs ayant des besoins eleves en lipoproteine de basse densite (ldl) a l'aide d'inhibiteurs de la proteine microsomale de transfert des triglycerides (mtp)
US6630502B2 (en) Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
AU712303C (en) Method for treating tumors having high LDL requirements employing MTP inhibitors
Ohmori et al. Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead